Gilead Sciences ( GILD )

Share Interview Share Compensation

$3.2B Part D

Peak10.0yr

Flagship asset representing 46% of total revenue; drives profitability and R&D reinvestment through 2036.

Help build intelligence for Gilead Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established HIV/hepatitis franchise generates predictable cash flow through 2033–2036 patent exclusivity, providing job security and long-term program continuity

Balanced commercial + R&D hiring (49 commercial + 50 R&D roles open) creates cross-functional advancement paths in a scaled, publicly traded organization

Watch Out For

Significant organizational restructuring: 448 employees laid off across 9 WARN filings since Jan 2025, including closures in Seattle (72 employees, Jan 2025) and mass layoffs in Foster City and Rockville (192 combined, Apr 2026)
Revenue stagnation ($27.3B FY2024 → $27.1B FY2025) and 46% reliance on single asset (BIKTARVY) create portfolio risk; $89M patent cliff (LETAIRIS, 2031) and weak pipeline limit future growth drivers

Generated by Claude from Gilead Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

EPCLUSA

Hepatitis C Virus

$877M Part D

Peak7.6yr

Core hepatitis C treatment generating $877M annually; protection extends to mid-2034 but faces declining prevalence as cure rates improve.

GENVOYA

$626M Part D

Peak6.4yr

Mature HIV integrase inhibitor now competing against newer fixed-dose combinations; patent cliff approaches 2033.

DESCOVY

$590M Part D

Peak9.6yr

NRTI backbone drug with longest patent horizon (2036); used in combination therapies and PrEP regimens.

ODEFSEY

Pulmonary Arterial Hypertension

$384M Part D

Peak6.2yr

Single-tablet HIV regimen with declining adoption; patent expires early 2033 as market shifts to integrase-based therapies.

VEMLIDY

Chronic Hepatitis B

$188M Part D

Peak6.2yr

First-in-class hepatitis B nucleotide with improved renal/bone safety profile; niche but loyal patient base.

LETAIRIS

$89M Part D

Peak4.9yr

Small endothelin receptor antagonist facing patent cliff in Oct 2031; modest revenue at highest near-term LOE risk.

HARVONI

Hepatitis C Virus

$55M Part D

Peak

Earlier-generation HCV NS5A/polymerase inhibitor now largely supplanted by EPCLUSA; minimal revenue contribution.

Pipeline & Clinical Trials

WelTel

Pre-Exposure Prophylaxis (PrEP)

N/A

LDV/SOF

Hepatitis C Virus

N/A

Neurological and Cognitive Dysfunction Following CAR-T Treatment. ICANS and Beyond

CAR T Cell Therapy

N/A

PrEP-RN

N/A

NewSpringForMe digital solution

Hematologic Diseases

N/A

Digital nutritional program

Metabolic Dysfunction-Associated Steatotic Liver Disease

N/A

Biopsies and bloood samplings

N/A

Financial Incentive

Pre-Exposure Prophylaxis

N/A

B/F/TAF

N/A

The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'

HIV Positive

N/A

Virtual clinical visits with home lab kits and mailed HIV PrEP

N/A

TelePrEP

Hiv

N/A

A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-H

Absence of Signs or Symptoms

N/A

Biospecimen Collection

N/A

A chatbot designed to promote PrEP awareness and uptake for Black MSM

N/A

Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patien

Coronary Microcirculation

N/A

Rnalozine

N/A

COVID-19

Hematopathology Eligible or CAR-t Cell Treatment

N/A

A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjec

Limited Scleroderma

N/A

French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)

N/A

Universal ART in a streamlined care model

Aspergillosis, Invasive Pulmonary

N/A

PCR based detection of azole resistance in A. fumigatus

N/A

Retrospective Audit

PrEP for Conception Purposes

N/A

There is no intervention

Diabetic Nephropathies

N/A

Thailand HDV Cohort

HDV

N/A

Hypertonic Saline

Healthy Subjects

N/A

PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples

N/A

Digital Health Feedback System

N/A

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe

N/A

Vuka+ application

Adherence, Medication

N/A

TruTag System

Hiv

N/A

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

N/A

Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)

N/A

WelTel

HIV Pre-exposure Prophylaxis

N/A

PrEP Care Anywhere Services

Adherence, Patient

N/A

PrEP Uptake with Rapid Start

N/A

I'm Fully Empowered for Her

N/A

Team Based Inpatient ARTAS

N/A

ELISA

N/A

Telehealth Coaching

Adolescent Behavior

N/A

Monitoring virus load

ART

N/A

HIV-HBV Co-Infection and Liver Disease

N/A

Colonoscopy

N/A

electronic medical record alert linked to orders

N/A

The RESPOND Outcomes Study

N/A

Gain framing plus demographically targeted photos

N/A

Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients

Systemic Sclerosis

N/A

Genetic Determinants of Kidney Disease in People of African Ancestry With HIV

HIV Nephropathy

N/A

Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromis

Invasive Aspergillosis

N/A

HIV test by oral swab